George Canellos

George Canellos is an icon of hematologic oncology who led the pivotal trial establishing ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) as the superior and less toxic alternative to MOPP for Hodgkin lymphoma, cementing it as the global standard of care for decades. He conducted foundational research at Dana-Farber and NCI that helped establish curative chemotherapy protocols for DLBCL, Hodgkin lymphoma, and breast cancer. His mentorship of generations of oncologists and prolific academic contributions define a career at the highest level of the specialty.